publication venue for
- The amyloid-β pathway in Alzheimer's disease: a plain language summary.. 13:141-149. 2023
- Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon β-1a users.. 13:151-159. 2023
- Friedreich ataxia: clinical features and new developments.. 12:267-283. 2022
- Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives.. 11:329-340. 2021
- Omaveloxolone: potential new agent for Friedreich ataxia.. 11:91-98. 2021
- Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings.. 9:149-172. 2019
- Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia.. 8:233-242. 2018
- IFN-γ for Friedreich ataxia: present evidence.. 5:497-504. 2015
- Testing family-centered, function-focused care in hospitalized persons with dementia.. 5:203-15. 2015
- The sleep-wake cycle and Alzheimer's disease: what do we know?. 4:351-62. 2014
- Activities of daily living: where do they fit in the diagnosis of Alzheimer's disease?. 2:483-491. 2012
- Using biomarkers to improve detection of Alzheimer's disease.. 1:127-139. 2011
- Personality and the risk factors for developing behavioral and psychological symptoms of dementia: a narrative review 2019
- Cannabinoids for the treatment of behavioral and psychological symptoms of dementia 2018